Compare Jabil Inc (JBL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Merck & Co., Inc. — how do they compare? Jabil Inc trades at $302.11 (market cap $31.35B), while Merck & Co., Inc. trades at $142.03 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 11.2× Jabil Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and Merck & Co., Inc. for 98 Days on average.
| JBL | MRK | |
|---|---|---|
Market Cap | $31.35B | $351.28B |
Volume | 1,337,978 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $385.50 | $156.43 |
52-Week Low | $192.49 | $82.49 |
Typical Hold Time | 23 Days | 98 Days |
Enterprise Value | $33.63B | $398.04B |
Dividend Yield | 0.11% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $299.47, down 3.14% amid bearish technical signals despite strong Q4 2026 earnings that beat estimates with EPS of $4.40 versus $4.07 expected. The stock shows neutral oscillators but bearish moving averages, with support at $296 and resistance at $303. Revenue grew to $29.80B in 2025 with net income of $657M, while 2026 projections indicate $36.0B revenue and $1.0B net income, supported by AI infrastructure demand.
Outlook remains positive with 60.87% analyst buy ratings and a $434.75 consensus price target implying 45% upside. Key risks include high debt levels and market volatility, but strong earnings momentum and AI-driven growth in fiscal 2027 provide investment opportunity. Monitor execution against guidance and macroeconomic conditions.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
